Updates are available Correction dated 2018-10-01
Click to view Correction: https://doi.org/10.1186/s12894-018-0397-5
-
Authors
Schultz, Neil M.
Shore, Neal D.
Chowdhury, Simon
Klotz, Laurence H.
Concepcion, Raoul S.
Penson, David F.
Karsh, Lawrence I.
Yang, Hongbo
Brown, Bruce A.
Barlev, Arie
Flanders, Scott C.
-
Funding
Funding for this research was provided by:
This research was funded by Astellas Pharma, Inc. and Medivation, Inc., which was acquired by Pfizer, Inc. in September 2016, the co-developers of enzalutamide.
- License Information
-
More Information
Article History
Received: 31 July 2017
Accepted: 23 August 2018
First Online: 6 September 2018
Change Date: 1 October 2018
Change Type: Correction
Change Details: It has been highlighted that in the original article [1] there was a typesetting mistake in the Results – NNT in Strive section. This Correction article states the incorrect and correct sentence.
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: NMS, SCF and BAB are employees of Astellas and own stock/stock options at the time of this manuscript, however, SCF and BAB are no longer employees presently of Astellas. AB was an employee of Medivation at the time of the study and owns stock/stock options. NDS has been a consultant/advisor for Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Medivation, Sanofi, Takeda, and Inovio and has participated in speaker bureaus for Janssen, Bayer, and Dendreon. SC has acted as a consultant/advisor for Astellas and Janssen and has participated in speaker bureaus for Janssen, Sanofi, Clovis Oncology, and Astellas. LHK reports honoraria for advisory board participation from Astellas, Medivation, Janssen, Amgen, Genomic Health, and AbbVie, outside the submitted work. RSC has been a consultant/advisor for CUSP, Integra Connect, and Dendreon and reports honoraria for participation in speaker bureaus for Astellas, Medivation, Janssen, Bayer, and Sanofi. DFP has been a consultant for Astellas, Medivation, and Dendreon. LIK has been a consultant for 3DBiopsy, Argos, Tokai, Takeda, Heat Biologics, Augmenix, Dendreon, Astellas, Bayer, Janssen, Medivation, and Sanofi, has participated in speaker bureaus for Astellas, Bayer, Janssen, Medivation, Amgen, and Dendreon, has received research funding from Astellas, Bayer, Janssen, Medivation, Sanofi, Spectrum, Ferring, Precision Biopsy, 3DBiopsy, Argos, Tokai, Takeda, Heat Biologics, Augmenix, and Dendreon through his institution, and owns stock options with Swan Valley Medical. HY is an employee of Analysis Group Inc., which has received consultancy fees from Astellas and Medivation.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
